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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized
by a progressive upper and lower motor neuron degeneration. One of the peculiar
clinical characteristics of ALS is the wide distribution in age of onset, which is probably
caused by different combinations of intrinsic and exogenous factors. We investigated
whether these modifying factors are converging into common pathogenic pathways
leading either to an early or a late disease onset. This would imply the identification of
phenotypic biomarkers, that can distinguish the two populations of ALS patients, and of
relevant pathways to consider in a therapeutic intervention. Toward this aim a differential
proteomic analysis was performed in peripheral blood mononuclear cells (PBMC) from
a group of 16 ALS patients with an age of onset ≤55 years and a group of 16 ALS
patients with an age of onset ≥75 years, and matched healthy controls. We identified
43 differentially expressed proteins in the two groups of patients. Gene ontology analysis
revealed that there was a significant enrichment in annotations associated with protein
folding and response to stress. We next validated a selected number of proteins
belonging to this functional group in 85 patients and 83 age- and sex-matched healthy
controls using immunoassays. The results of the validation study confirmed that there
was a decreased level of peptidyl-prolyl cis-trans isomerase A (also known as cyclophilin
A), heat shock protein HSP 90-alpha, 78 kDa glucose-regulated protein (also known as
BiP) and protein deglycase DJ-1 in PBMC of ALS patients with an early onset. Similar
results were obtained in PBMC and spinal cord from two SOD1G93A mouse models with
an early and late disease onset. This study suggests that a different ability to upregulate
proteins involved in proteostasis, such as foldase and chaperone proteins, may be at the
basis of a different susceptibility to ALS, putting forward the development of therapeutic
approaches aiming at boosting the protein quality control system.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease characterized by a progressive upper and lower motor
neuron degeneration. ALS is a highly heterogeneous disorder,
with phenotypic variability involving a number of clinical
aspects such as site of onset, age of onset, rate of progression,
nonmotor involvement and response to therapy (Beghi et al.,
2011). This makes it difficult to decipher pathogenesis and
to develop therapeutic strategies, also because biomarkers that
reflect heterogeneity and may be useful for stratification are
missing. A combination of genetic and environmental/exogenous
modifying factors are believed to underlie this variability. The
identification of the pathways affected by the modifying factors
is of great interest, as they may be targets of therapeutic
intervention.
Age is a known risk factor for ALS. The majority of ALS
patients have disease onset between 55 and 75 years of age,
however patients with an age of onset <55 years and >75 years
do exist and represent, respectively, the 22% and the 16% of
all patients, as recently reported in a large multicenter Italian
study (Calvo et al., 2016). Several factors, both genetic and
environmental/exogenous, have been reported to modify age of
onset in patients and animal models of ALS. FUS mutations have
been frequently associated with early-onset disease in familial and
sporadic cases (Chiò et al., 2009; Hübers et al., 2015). Earlier
onset of ALS has been also observed in soldiers and professional
soccer players (Haley, 2003; Chiò et al., 2005; Pupillo et al.,
2012). In these patients, an anticipated onset might be linked to
heavy physical exercise, repeated trauma, and/or exposure to as
yet unknown toxic agents in genetically predisposed individuals
(Beghi and Morrison, 2005; Pupillo et al., 2012; Beghi, 2013).
A mutant SOD1G93A mouse model of ALS on a 129Sv genetic
background has an earlier age of onset than a SOD1G93A
mouse model on a C57BL6 genetic background despite an equal
expression of the mutant protein (Marino et al., 2015). These
mice have also faster disease progression and an intrinsic marked
down-regulation of specific pathways involved in mitochondrial
function and protein quality control (Nardo et al., 2013, 2016;
Marino et al., 2015). Conversely, ApoE2 polymorphism and lower
EPHA4 expression have been correlated with delayed age of
onset in ALS patients (Li et al., 2004; Van Hoecke et al., 2012).
Moreover, in mutant SOD1 mice female showed a later onset than
male and this delay further increased with exercise (Veldink et al.,
2003).
Summarizing, different combinations of intrinsic and
exogenous factors, that can be hardly discerned, may lead to
an anticipated or a delayed onset of the disease. We wanted
to test whether or not modifying factors are converging into
common pathogenic pathways leading either to an early or
a late disease onset. This would imply the identification of
phenotypic biomarkers, that can distinguish the two populations
of ALS patients, and of relevant pathways to consider in a
therapeutic intervention. Toward this aim a significant cohort
of incident ALS patients with either early (<55 years of age)
or late (>75 years of age) disease onset was recruited from
population-based Italian registries, and several analyses were
performed. We found that an epigenetic rearrangement such
as whole-blood DNA methylation could not distinguish the
two groups of ALS patients (Tremolizzo et al., 2014). However,
difference in plasma amino acid levels were observed in relation
to the age of onset (Cecchi et al., 2014). In this work, we identified
protein phenotypic biomarkers in peripheral blood mononuclear
cells (PBMC) of the same cohort of patients indicating that
protein levels in PBMC could be good biological correlates
of the age of onset in ALS. The same phenotypic biomarkers
were also analyzed in the two mutant SOD1 mouse models
of ALS with early and late disease onset indicating common
changes between the sporadic and SOD1-linked forms. These
biomarkers are proteins involved in the maintenance of protein
homeostasis, or proteostasis. Proteostasis is attained through
several quality-control systems that assist protein folding, clear
misfolded proteins and respond to protein aggregation, whose
major players are molecular chaperones. Interestingly, impaired
proteostasis has emerged as a key contributor to the pathogenesis
of ALS (Ruegsegger and Saxena, 2016).
MATERIALS AND METHODS
Antibodies
The antibodies for Western and dot blot, used for human
and mouse samples, were: rabbit polyclonal anti-peptidyl-
prolyl cis-trans isomerase A (PPIA) antibody (1:2500 dilution;
Millipore), rabbit polyclonal anti-heat shock protein HSP 90-
alpha (HSP90) (1:3000 dilution; Stressgen), rabbit polyclonal
anti-78 kDa glucose-regulated protein (GRP78) (1:500 dilution;
Santa Cruz Biotechnology Inc.), mouse monoclonal anti-
endoplasmic reticulum protein 57 (ERp57) (1:2500 dilution;
Stressgen), rabbit monoclonal anti-protein deglycase DJ-1
(DJ-1) (1:1500 dilution; Abcam), mouse monoclonal anti-
heat shock cognate 71 kDa protein (HSC70) (1:1000 dilution;
Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-TDP-43
(1:2500 dilution; Proteintech), goat anti-mouse or anti-rabbit
peroxidase-conjugated secondary antibodies (1:5000; Santa Cruz
Biotechnology Inc.).
Subjects
Following approval of the protocol by the ethics committees
(Comitato Etico Interaziendale A.O.U. San Giovanni Battista
di Torino – A.O. “C.T.O. Maria Adelaide di Torino”, Torino,
Italy; Comitato etico degli Spedali Civili di Brescia, Brescia,
Italy; Comitato Etico Provinciale di Modena, Modena, Italy)
written informed consent was obtained from all participating
subjects. Patients, enrolled in three Italian population-based
registries (Lombardia, Piemonte, Emilia Romagna), were newly
diagnosed definite, probable or possible ALS, according to the
El Escorial criteria (Brooks, 1994). To be eligible, patients
had to be ≤55 years of age (early ALS) or ≥75 years of
age (late ALS) at diagnosis. Controls were residency-, sex-,
and age-matched (±5 years), randomly chosen within the
same hospital of the patient among subjects admitted for
surgery for a non-spontaneously evolving disease. Subjects
enrolled for the discovery phase study were 16 early ALS,
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16 late ALS and 32 controls (early and late controls), with
demographic and clinical characteristics described in Table 1.
Subjects enrolled in the validation study were 85 ALS patients
and 83 controls with demographic and clinical characteristics
described in Table 2. All cases were sporadic. A wide, although
partial screening for ALS-causative mutations was performed
(Tremolizzo et al., 2014). Two early ALS cases carried a
TARDP mutation (M359V, G368S), one late ALS case carried a
SOD1 mutation (D90A) and another one an OPTN mutation
(L500P).
Mice
Procedures involving animals and their care were approved
by the Institutional Animal Care and Use Committee and
were conducted in conformity with the following laws,
regulations, and policies governing the care and use of
laboratory animals: Italian Governing Law (D.lgs 26/2014;
Authorisation n.19/2008-A issued March 6, 2008 by Ministry
of Health); Mario Negri Institutional Regulations and Policies
providing internal authorization for persons conducting animal
experiments (Quality Management System Certificate – UNI
EN ISO 9001:2008 – Reg. No. 6121); the NIH Guide for the
Care and Use of Laboratory Animals (2011 edition) and EU
directives and guidelines (EEC Council Directive 2010/63/UE).
The Statement of Compliance (Assurance) with the Public
Health Service (PHS) Policy on Human Care and Use of
Laboratory Animals has been recently reviewed (9/9/2014) and
will expire on September 30, 2019 (Animal Welfare Assurance
#A5023-01). Animals were bred and maintained at the IRCCS-
Istituto di Ricerche Farmacologiche Mario Negri, Milan under
standard conditions, temperature 21 ± 1◦C, relative humidity
55 ± 10%, 12h light schedule, food and water ad libitum.
Transgenic SOD1G93A mice expressing about 20 copies of
mutant human SOD1 with a Gly93Ala substitution (B6SJL-
TgSOD1G93A-1Gur) were originally obtained from Jackson
Laboratories and maintained on a C57BL/6JOlaHsd (C57)
genetic background at Harlan Italy S.R.L., Bresso, Milan,
Italy. By crossbreeding C57 SOD1G93A mice with 129S2/SvHsd
(129Sv) mice for >15 generations, SOD1G93A mice on a 129Sv
homogenous background were generated (Marino et al., 2015).
For biochemical analyses, female mice were deeply anesthetized
with ketamine hydrochloride (IMALGENE, 150 mg/kg, Alcyon
Italia S.p.A.) and medetomidine hydrochloride (DOMITOR,
2 mg/kg, Alcyon Italia S.p.A.) by intraperitoneal injection
and euthanized by decapitation at symptom onset: for 129Sv
SOD1G93A mice at 14 weeks of age, and for C57 SOD1G93A
mice at 17 weeks of age. The corresponding age-matched
nontransgenic mice were used as controls.
PBMC Isolation and Protein Extraction
Peripheral blood mononuclear cells were isolated from peripheral
venous blood of human subjects essentially as previously
described (Nardo et al., 2011). Briefly, samples of blood
were collected in EDTA pre-coated tubes (BD Vacutainer
K2EDTA) and PBMC were isolated from EDTA blood by
Ficoll-Hypaque (Ficoll-PlaqueTM Plus, GE Healthcare) density
gradient centrifugation at 800 × g for 30 min at 18–20◦C.
Mononuclear cells were collected from the interface and washed
three times with RPMI 1640 medium (EuroClone). Platelets
were eliminated by an additional wash and centrifugation
at 200 × g for 10 min. PBMC were stored as pellets at
–80◦C. PBMC from mice were isolated from blood sampled by
intracardiac puncture and collected in EDTA pre-coated vials
(BD Vacutainer K2EDTA). PBMC were isolated from EDTA-
blood by Lympholite (Lympholyte-Mammal, Cedarlane) density
gradient centrifugation at 1000 × g for 25 min at 18–20◦C.
TABLE 1 | Demographic and clinical characteristics of the enrolled population in the proteomic study.
Residency Diagnosis Agea Sex Formb Scorec Durationd N
Lombardia Early ALS 50 ± 5 4(M), 4(F) 8(S) 30 ± 11 16 ± 7 8
Early Controls 48 ± 5 4(M), 4(F) n/a n/a n/a 8
Late ALS 78 ± 2 4(M), 4(F) 4(S), 1(B), 3(–) 29 ± 10 14 ± 5 8
Late Controls 77 ± 4 2(M), 6(F) n/a n/a n/a 8
Piemonte Early ALS 47 ± 6 2(M), 2(F) 1(S), 3(B) 37 ± 11 15 ± 4 4
Early Controls 49 ± 7 2(M), 2(F) n/a n/a n/a 4
Late ALS 81 ± 4 3(M), 1(F) 3(S), 1(B) 33 ± 9 15 ± 4 4
Late Controls 79 ± 4 3(M), 1(F) n/a n/a n/a 4
Emilia Romagna Early ALS 53 ± 3 2(M), 2(F) 2(S), 2(B) 43 ± 4 16 ± 3 4
Early Controls 55 ± 3 2(M), 2(F) n/a n/a n/a 4
Late ALS 82 ± 5 3(M), 1(F) 4(B) 21 ± 11 16 ± 5 4
Late Controls 83 ± 6 3(M), 1(F) n/a n/a n/a 4
Study population Early ALS 50 ± 5 8(M), 8(F) 11(S), 5(B) 28 ± 10 15 ± 4 16
Early Controls 50 ± 6 8(M), 8(F) n/a n/a n/a 16
Late ALS 80 ± 4 8(M), 8(F) 7(S), 6(B), 3(–) 14 ± 6 15 ± 5 16
Late Controls 79 ± 5 8(M), 8(F) n/a n/a n/a 16
aAge: age at peripheral blood mononuclear cells (PBMC) collection; bForm: spinal (S) or bulbar (B) form of amyotrophic lateral sclerosis (ALS); cScore: ALS Functional
Rating Scale Revised at PBMC collection; dDuration: disease duration (months) from the onset of symptoms to PBMC collection; n/a: not applicable; –: data not available.
Values are expressed as mean ± SD.
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TABLE 2 | Demographic and clinical characteristics of the enrolled population in the validation study.
Residency Diagnosis Agea Sex Formb Scorec Durationd N
Lombardia Early ALS 47 ± 6 9(M), 6(F) 13(S), 2(B) 36 ± 6 21 ± 19 15
Early Controls 47 ± 7 9(M), 7(F) n/a n/a n/a 16
Late ALS 78 ± 8 8(M), 9(F) 10(S), 7(B) 27 ± 10 21 ± 14 17
Late Controls 78 ± 5 7(M), 9(F) n/a n/a n/a 16
Piemonte Early ALS 48 ± 4 6(M), 1(F) 7(S) 37 ± 10 21 ± 22 7
Early Controls 48 ± 8 6 (M), 1(F) n/a n/a n/a 7
Late ALS 80 ± 4 7(M), 9(F) 10(S), 6(B) 32 ± 9 17 ± 17 16
Late Controls 80 ± 6 7(M), 9(F) n/a n/a n/a 16
Emilia Romagna Early ALS 46 ± 7 6(M), 10(F) 11(S), 5(B) 33 ± 11 38 ± 17 16
Early Controls 45 ± 9 8(M), 4(F) n/a n/a n/a 12
Late ALS 82 ± 6 6(M), 8(F) 7(S), 7(B) 27 ± 12 17 ± 10 14
Late Controls 80 ± 6 8(M), 8(F) n/a n/a n/a 16
Study population Early ALS 47 ± 6 21(M), 17(F) 31(S), 7(B) 29 ± 20 29 ± 20 38
Early Controls 46 ± 8 23(M), 12(F) n/a n/a n/a 35
Late ALS 80 ± 5 31(M), 26(F) 27(S), 20(B) 28 ± 10 19 ± 14 47
Late Controls 79 ± 5 22(M), 26(F) n/a n/a n/a 48
aAge: age at PBMC collection; bForm: spinal (S) or bulbar (B) form of ALS; cScore: ALS Functional Rating Scale Revised at PBMC collection; dDuration: disease duration
(months) from the onset of symptoms to PBMC collection; n/a: not applicable. Values are expressed as mean ± SD.
Mononuclear cells were harvested from the interface and washed
once at 800 × g for 10 min with RPMI 1640 (EuroClone)
supplemented with 2.5 mM EDTA, and stored as pellets at –80◦C.
Before analysis human and mouse PBMC were lysed in 20 mM
Tris-HCl pH 7.5, 0.1% NP40, and 0.1% SDS supplemented with
Protease Inhibitors (Sigma), boiled for 5 min and centrifuged at
16.000 × g for 10 min at 4◦C. Supernatants were analyzed by
Western and dot blot analyses. Proteins were quantified by the
BCA protein assay (Pierce).
Protein Extraction from the Spinal Cord
of the Mice
The spinal cord was flushed from the vertebral column and
sectioned into cervical, thoracic and lumbar segments. The
samples were immediately frozen on dry-ice and stored at
–80◦C until analysis. Lumbar spinal cords were homogenized by
sonication in 1% boiling SDS. Protein homogenates were further
boiled for 10 min and centrifuged at 13.500× g for 5 min at 4◦C.
Supernatants were analyzed by Western and dot blot analyses.
Proteins were quantified by the BCA protein assay (Pierce).
Two-Dimensional Difference in Gel
Electrophoresis (2D DIGE)
Peripheral blood mononuclear cells proteins were prepared for
2D DIGE analysis as follows: four pools of 20 µg from 16 early
ALS, 16 early controls, 16 late ALS, and 16 late controls were
methanol-precipitated overnight. Proteins were then dissolved
in 30 mM Tris-HCl pH 8.5, 7 M urea, 2 M thiourea, CHAPS
4% (w/v) and Cydye-labeled according to the manufacturer’s
instructions (GE Healthcare) with minor modifications. Briefly,
20 µg of each pool was labeled with 200 pmol of Cy3 or Cy5
dye for 30 min in ice in the dark. To exclude preferential labeling
of the dyes, each sample was also reverse labeled. As an internal
standard, aliquots of each pool were mixed and labeled with
Cy2 dye. Labeled samples were then resuspended in Destreak
SolutionTM (GE Healthcare) with IPG buffer pH 3-11 NL 1%
v/v (GE Healthcare) and loaded into 11 cm-IPG strips pI range
3-11NL (GE Healthcare). Isoelectrofocusing was done on an
IPGphor apparatus (GE Healthcare) with the following protocol:
300 Vhrs at 30 V, 50 Vhrs at 200 V, 1500 Vhrs at 2000 V,
2800 Vhrs of a linear gradient up to 3500 V, 4800 Vhrs at 3500 V,
8500 Vhr of a linear gradient up to 8000 V, and 30000 Vhr
at 8000 V. SDS-PAGE was done using Precast Tris-HCl 10%
polyacrylamide SDS gel (Biorad). Eight 2D gels were run with the
four experimental groups. Each gel contained two experimental
groups, one Cy3-labeled, the other Cy5-labeled plus the Cy2-
labeled internal standard. Gel images were captured by the laser
scanner Molecular Imager FX (Bio-Rad). Image analysis was
done with Progenesis Same Spot software (Nonlinear Dynamics).
For each spot the normalized volume was standardized against
internal standard spot normal volume. The values for each
spot in each group were expressed as the mean of the Cy3-
and Cy5-labeled analyses. Values for early and late ALS were
further normalized to the means values of early and late controls,
respectively. Differential spots were considered only those that
had a fold change (normalized late ALS/ normalized early ALS)
≤0.8 or ≥1.3.
Protein Identification
Differential protein spots were located and excised from 2D
gels with the EXQuestTM spot cutter (Bio-Rad). Spots were
processed and gel-digested with modified trypsin from bovine
pancreas (Roche) and identified by mass spectrometry (MS),
as previously described (Nardo et al., 2011). Peptide mass
fingerprinting and tandem MS/MS were done on a 4800
MALDI TOF/TOF mass spectrometer (Applied Biosystems). The
mass spectra were internally calibrated with trypsin autolysis
fragments. The five most abundant precursor ions, out of the
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exclusion mass list (ions from human keratin and trypsin),
were selected for MS/MS analysis. The combined MS and
MS/MS data were submitted by GPS Explorer v.3.6 software
(Applied Biosystems) to the MASCOT database search engine
(Version 2.1, Matrix Science) and searched with the following
parameters: Uniprot_Swissprot 2012x database over all Homo
sapiens protein sequences deposited, no fixed modifications, as
possible modifications carboamidomethylation of cysteine and
oxidation of methionine, 1 missed trypsin cleavage, a mass
tolerance of ±0.1 Da for the peptide masses and ±0.3 Da for the
MS/MS fragment ion masses. A protein was regarded as identified
if the MASCOT protein score, based on the combined MS and
MS/MS data, was above the 5% significance threshold for the
database (Pappin et al., 1993).
Gene Ontology (GO) Analysis
Identified proteins were classified on the basis of gene ontology
(GO) annotations provided by PANTHER1 (Mi et al., 2013).
PANTHER overrepresentation test was performed with the list
of the identified differential proteins against the whole Homo
sapiens reference list and against a list of about 800 proteins
extracted from published works of 2D-based proteomics of
lymphocytes/monocytes (Verhoeckx et al., 2004; Rosengren et al.,
2005; Xie et al., 2005; Azkargorta et al., 2006; Han et al., 2006;
Huang et al., 2006; Ramirez-Boo et al., 2006; Salonen et al.,
2006; Zada et al., 2006; Henrich et al., 2007; Lai et al., 2007;
Rakkola et al., 2007; Skopeliti et al., 2007; Vergara et al., 2008).
PANTHER GO-Slim Biological Process and GO-Slim Molecular
Function were used as annotation data sets (version 11.1, released
2016-07-15).
Dot Blot Analysis
Dot blot was used in the validation study after verification that
the antibody detected specific bands in WB (Supplementary
Figure S1). Proteins (3 µg) were directly loaded onto
nitrocellulose Trans-Blot transfer 0.2–0.45 µm (Bio-Rad)
membranes, depositing each sample on the membrane by
vacuum filtration, as described previously (Nardo et al., 2011).
An internal standard which is a pool of all samples in the analysis
(healthy controls and patients) was deposited in triplicates. Dot
blot membranes were blocked with 3% (w/v) BSA (Sigma) and
0.1% (v/v) Tween 20 in Tris-buffered saline, pH 7.5, incubated
with primary antibodies, then with peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology Inc.). Blots were
developed with LuminataTM Forte Western Chemiluminescent
HRP Substrate (Millipore) on the ChemiDoc XRS system
(Bio-Rad). Densitometry was done with Progenesis PG240 v2006
software (Nonlinear Dynamics). The immunoreactivity of the
different proteins was normalized to Ponceau Red staining
(Fluka) and to the internal standard of each membrane.
Statistical Analysis
Immunoreactivity values for each protein analyzed in early and
late ALS were normalized to the means values of early and
late controls, respectively. The statistical analysis of the protein
1http://www.pantherdb.org/
expression in the two groups was done by Student’s t-test using
PRISM software (GraphPad, San Diego, CA, USA, version 6.01).
RESULTS
Identification of Candidate Phenotypic
Biomarkers of ALS in PBMC by
2D-DIGE-Based Proteomics
Figure 1A schematically shows the strategy we used to identify
and validate phenotypic protein biomarkers of ALS in PBMC.
In the discovery phase, PBMC of ALS patients with ≤55 years
of age (early ALS, EA) or ≥75 years of age (late ALS) at
diagnosis and matched early and late controls were analyzed by
2D DIGE. The analysis was done with 16 pooled samples for
each of the four experimental groups (Table 1). Spot volume
values for early and late ALS were normalized to the mean values
of early and late controls, respectively. Spots were considered
differential if fold change (normalized late ALS/normalized early
ALS) was ≤0.8 or ≥1.3. A total of 68 differential spots were
detected (Figure 1B). From these spots 43 unique proteins were
identified by MS as candidate protein biomarkers (Table 3).
Some of the proteins were identified in multiple spots at
different pI and Mw, which are fragments or post-translationally
modified isoforms of the same protein (Supplementary Table S1).
We grouped the differential proteins on the basis of their
most recognized function and on GO annotations (Table 3).
The overrepresentation test performed with the list of the
differential proteins against the Homo sapiens reference list
indicated isomerase activity (GO:0016853), associated with PPIA
and ERp57, among the most significantly enriched (p = 0.03;
fold = 7.8) molecular functions. Protein folding (GO:0006457)
and response to stress (GO:0006950) were among the most
significantly enriched (p < 0.01; fold>4) biological processes
identified. The overrepresentation test performed also against
a reference list of lymphocyte/monocyte proteins, identified in
2D-based proteomic studies, indicated response to stress as
one of the most significantly enriched (p = 0.03; fold = 2.5)
biological processes. This suggested that proteins associated with
these molecular functions and biological processes (Table 3),
such as PPIA, HSP90, GRP78, ERp57, and DJ-1, were attracting
candidate phenotypic biomarkers to further validate in a larger
and well-characterized cohort of patients with early and late
disease onset.
Validation of Candidate Phenotypic
Biomarkers
In the validation study, we analyzed total protein levels of
candidate phenotypic biomarkers, PPIA, HSP90, GRP78, ERp57,
and DJ-1, by dot blot analysis in PBMC samples from an
independent set of ALS patients (n = 85), n = 38 early ALS and
n = 47 late ALS, and matched controls (n = 83), n = 35 early
controls and n = 48 late controls (Table 2). Immunoreactivity
values for each protein in early and late ALS patients were
normalized to the mean values of early and late controls,
respectively, similarly to the proteomic analysis. We found that
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FIGURE 1 | Identification of phenotypic biomarkers in PBMC of early and late ALS patients. (A) Scheme of the strategy to identify phenotypic protein
biomarkers in PBMC of patients early onset ALS (EA) and late-onset ALS (LA) and matched controls, early (EC), and late (LC). 2D-DIGE analysis was done with 16
pooled samples for each experimental group and spot volume values for EA and LA were normalized to EC and LC, respectively (nEA, nLA). Spots were considered
differential if fold change (nLA/nEA) was ≤0.8 or ≥1.3 and identified by mass spectrometry (MS, Supplementary Table S1). Differential proteins were classified on the
basis of GO annotations and a selected number of proteins associated with “protein folding and response to stress” biological function was validated by dot blot
immunoassays. (B) Representative Sypro-Ruby stained 2D gel of the PBMC proteome. The numbered spots correspond to the differential proteins listed in Table 3
and Supplementary Table S1.
PPIA, HSP90, GRP78, and DJ-1 were significantly lower in
early ALS than in late ALS, and therefore can be considered
phenotypic biomarkers (Figures 2A–C,E), while ERp57 did not
change (Figure 2D). Moreover, PPIA, HSP90, GRP78, and DJ-
1 were similarly regulated, with a decreased level in early ALS
compared to early controls and an opposite tendency in late
ALS (Supplementary Figures S2A–C,E), suggesting that early ALS
patients have some defects in the response to stress pathways.
In the same validation analysis, we measured another chaperone
protein, HSC70, and TDP-43, both not differential in the 2D-
DIGE analysis, but up-regulated in PBMC of a cohort of ALS
patients with a mean age of onset of 62 ± 10 years, previously
reported in a work by our laboratory (Nardo et al., 2011). We
found that HSC70 could not distinguish early from late ALS
(Figure 2F), but it was up-regulated in late ALS compared to
controls (Supplementary Figure S2F). We confirmed that total
TDP-43 protein levels in PBMC underscores disease (Figure 2G),
in fact it was higher in both early and late ALS compared to
controls, but could not discriminate early ALS from late ALS
(Figure 2H). It has to be noted that in our assay the total TDP-
43 protein level comprise the 43-kDa full-length and fragmented
forms (Supplementary Figure S1A).
The experimental set up of the analysis has strengths and
limitations. The major strengths are the population base and the
enrolment of patients with newly diagnosed ALS. Our patients
are a fairly representative sample of an incident ALS population.
The major limitation is the small sample size. The analysis
may thus be underpowered for some differences to achieve
statistical significance. Then, we did not adjust our data for
multiple comparisons. Thus, we cannot exclude that some of the
associations are chance findings. However, due to the exploratory
nature of the analysis, we deliberately decided not to use the
Bonferroni correction for multiple testing.
Analysis of Phenotypic Biomarkers in
Two SOD1G93A Mouse Models with
Different Age of Onset
We also analyzed total protein levels of the candidate phenotypic
biomarkers, PPIA, HSP90, GRP78, ERp57, and DJ-1 in PBMC
of two SOD1G93A mouse models, 129Sv SOD1G93A and C57
SOD1G93A mice and corresponding non-transgenic controls by
dot blot analysis. These mice despite having equal SOD1G93A
expression have a different disease phenotype, because of the
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TABLE 3 | Differential spots.
Spot Uniprot Protein name Fold change
Cytoskeleton-associated proteins
1a-h P18206 Vinculin 1.6
2a-c P06396 Gelsolin 2.1
7 P12814 Alpha-actinin-1 1.6
12 O75083 WD repeat-containing protein 1 1.3
21a-d P63261 Actin, cytoplasmic 2 1.8
22 P60709 Actin, cytoplasmic 1 1.4
24a-b P52907 F-actin-capping protein subunit alpha-1 0.7
Protein folding and response to stress
5 P14625 Endoplasmin 1.4
8 P07900 Heat shock protein HSP 90-alpha (HSP90) 1.3
9 P11021 78 kDa glucose-regulated protein (GRP78) 1.3
19 P27797 Calreticulin 1.3
20 P30101 Protein disulfide-isomerase A3 (ERp57) 1.3
32 P30041 Peroxiredoxin-6 0.7
33 P09211 Glutathione S-transferase P 0.8
34 Q99497 Protein deglycase DJ-1 (DJ-1) 0.7
36a-b P62937 Peptidyl-prolyl cis-trans isomerase A (PPIA) 0.8
29 P23396 40S ribosomal protein S3 0.6
43 P02775 Platalet basic protein (CXCL7) 1.3
Metabolic processes
11 P29401 Transketolase 0.8
13a-c P14618 Pyruvate kinase isozymes M1/M2 1.4
14 P14619 Pyruvate kinase isozymes M1/M3 1.3
15a-b P11413 Glucose-6-phosphate 1-dehydrogenase 1.3
16 P00367 Glutamate dehydrogenase 1, mitochondrial 1.4
25 P11172 Uridine 5′-monophosphate synthase 0.7
31 O95336 6-Phosphogluconolactonase 1.3
Inflammatory response
39a-b P06702 Protein S100 A9 0.7
42a-b P05109 Protein S100 A8 0.6
26 P04083 Annexin A1 0.6
Signal transduction
27 P63104 14-3-3 protein zeta/delta 1.3
28a Q15404 Ras suppressor protein 1 0.7
28b Q15404 Ras suppressor protein 1 1.3
30 P52566 Rho GDP-dissociation inhibitor 2 0.7
Others
3a P07996 Thrombospondin-1 0.7
3b P07996 Thrombospondin-1 1.7
4 P35442 Thrombospondin-2 1.5
6 P08514 Integrin alpha-IIb 1.5
18 P52272 Heterogeneous nuclear ribonucleoprotein M 1.3
35 P37802 Transgelin-2 1.3
37 P61088 Ubiquitin-conjugating enzyme E2 N 0.5
40 Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3 1.3
41 P58546 Myotrophin 0.7
Blood contaminant
10 P02768 Serum albumin 1.3
17a-b P02671 Fibrinogen beta chain 1.4
23 P02679 Fibrinogen gamma chain 1.9
38a-d P68871 Hemoglobin subunit beta 0.6
Uniprot: entry from the UniProt Knowledgebase database; Fold change: spot volume fold change (nLA/nEA), in case of multiple spots of the same protein with a similar
trend, mean fold change is reported. Mass spectrometry (MS) data for each spot are reported in Supplementary Table S1. In bold the proteins analyzed in the validation
study.
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FIGURE 2 | Validation of candidate phenotypic biomarkers in PBMC of early and late ALS patients. (A–H) PPIA, HSP90, GRP78, ERp57, DJ-1, HSC70,
and TDP-43 were analyzed by dot blot immunoassays in PBMC samples from an independent set of ALS patients (n = 85), n = 38 EA and n = 47 LA, and matched
controls (n = 83), n = 35 EC and n = 48 LC. Immunoreactivity was normalized to protein loading, as assessed by Ponceau Red staining, and then to the mean values
of matched controls (A–F,H). We found that PPIA, HSP90, GRP78, and DJ-1 were significantly lower in early ALS than in late ALS (A–C,E) and that TDP-43 was
higher in both early and late ALS compared to matched controls (G). ∗p < 0.05, by Student’s t-test.
different genetic background (Marino et al., 2015). In particular,
129Sv and C57 SOD1G93A mice have symptom onset at 14 and
17 weeks of age, respectively, thus representing our mouse models
of early (129Sv) and late (C57) disease onset. Similarly, to the
human samples, immunoreactivity values for each protein in
early and late mouse models were normalized to the mean values
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 April 2017 | Volume 10 | Article 99
fnmol-10-00099 April 6, 2017 Time: 11:30 # 9
Filareti et al. Phenotypic Protein Biomarkers of ALS
FIGURE 3 | Analysis of phenotypic biomarkers in PBMC of SOD1G93A mouse models with early (129Sv) and late (C57) disease onset. (A–F) PPIA,
HSP90, GRP78, ERp57, DJ-1, and TDP-43 were analyzed by dot blot immunoassays in PBMC samples (n = 5 per group) from 129Sv SOD1G93A and C57
SOD1G93A (G93A) mice at disease onset, respectively, at 14 and 17 weeks of age, and matched non-transgenic controls (Ntg). Immunoreactivity was normalized to
protein loading, as assessed by Ponceau Red staining, and then to the mean values of matched controls. We found that PPIA, HSP90 were significantly lower in
early ALS than in late ALS (A,B) similarly to human samples. ∗p < 0.05, by Student’s t-test.
of the corresponding non-transgenic controls. We found that
PPIA and HSP90 were significantly lower in early SOD1G93A
mice than in late SOD1G93A mice, as much as in the human
samples (Figures 3A,B), and there was a significant lower level
of the two proteins in the early SOD1G93A mice compared to
their non-transgenic controls (Supplementary Figures S3A,B).
DJ-1 had a similar behavior but it did not reach statistical
significance (Figure 3E and Supplementary Figure S3E). GRP78
was instead significantly higher in early SOD1G93A mice than
in late SOD1G93A mice (Figure 3C), in contrast with the
human samples, with an increased level in the early SOD1G93A
mice compared to controls (Supplementary Figure S3C). ERp57
was not significantly different in late and early SOD1G93A
mice, as much as in the human samples (Figure 3D), but it
was significantly lower in late SOD1G93A mice compared to
controls (Supplementary Figure S3D). Finally, TDP-43 was not
significantly different in early and late SOD1G93A mice, as in
the human samples (Figure 3F), but was not different compared
to corresponding nontransgenic controls, in contrast with the
human samples (Supplementary Figure S3F).
Total protein levels of PPIA, HSP90, GRP78, DJ-1, and TDP-
43 were also measured in lumbar spinal cord homogenates
from the early and late SOD1G93A mice at disease onset and
relative age-matched nontransgenic controls by dot blot analysis
(Figure 4 and Supplementary Figure S4). PPIA, HSP90, GRP78
and DJ-1 were significantly lower in early SOD1G93A mice than
in late SOD1G93A mice (Figures 4A–C,E) and were similarly
regulated to PBMC isolated from patients (Supplementary
Figures S4A–E), indicating that also early SOD1G93A mice have
some defects in the response to stress pathways, as already
reported (Nardo et al., 2013, 2016; Marino et al., 2015). ERp57
and TDP-43 were not different in the two conditions as in
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FIGURE 4 | Analysis of phenotypic biomarkers in lumbar spinal cord of SOD1G93A mouse models with early (129Sv) and late (C57) disease onset.
(A–F) PPIA, HSP90, GRP78, ERp57, DJ-1, and TDP-43 were analyzed by dot blot immunoassays in lumbar spinal cord samples (n = 5 per group) from 129Sv
SOD1G93A and C57 SOD1G93A (G93A) mice at disease onset, respectively, at 14 and 17 weeks of age, and matched non-transgenic controls (Ntg).
Immunoreactivity was normalized to protein loading, as assessed by Ponceau Red staining, and then to the mean values of matched controls. We found that PPIA,
HSP90, GRP78, and DJ-1 were significantly lower in early ALS than in late ALS (A–C,E) similarly to PBMC from patients. ∗p < 0.05, by Student’s t-test.
the human samples (Figures 4D,F). These data confirmed a
previous work where no differences in total soluble TDP-43 were
found between the SOD1G93A mice and respective Ntg littermates
and between the two mouse strains (Marino et al., 2015). In
conclusion, we observed a similar regulation of these proteins, in
PBMC of patients and PBMC and spinal cord of mice (Table 4).
DISCUSSION
The molecular determinants of ALS heterogeneity are still
poorly understood. An anticipated or a delayed onset of the
disease may be caused by various combinations of intrinsic and
exogenous factors converging into common pathogenic pathways
that underlie different susceptibility to ALS and eventually lead
to a different prognosis. Here we report the identification of
protein biomarkers in PBMC that can discriminate ALS patients
TABLE 4 | Summary of the biomarker analysis in early and late ALS.
SAMPLES PPIA HSP90 GRP78 ERp57 DJ-1 TDP-43
Human PBMC ↓ ↓ ↓ ↔ ↓ ↔
Mouse PBMC ↓ ↓ ↑ ↔ ↔ ↔
Mouse spinal cord ↓ ↓ ↓ ↔ ↓ ↔
↓, significantly lower in early onset disease; ↔, not significantly different;
↑, significantly higher in early onset disease.
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with an early disease onset from those with a late disease onset.
The identified phenotypic biomarkers have in common a high
expression in CNS where they have an important role in protein
folding, as foldases and/or classical molecular chaperones, and
are upregulated by a variety of stressors. They participate
at different levels and in different ways in the maintenance
of proteostasis, whose deficit has shown to generate protein
misfolding and aggregation and facilitate the development of
several neurodegenerative diseases, including ALS (Ruegsegger
and Saxena, 2016). These phenotypic biomarkers are: PPIA,
HSP90, GRP78, and DJ-1.
Polyclonal anti-peptidyl-prolyl cis-trans isomerase A is
ubiquitously expressed, with the highest expression in neurons
and motor neurons (Lauranzano et al., 2015). It is a peptidylprolyl
cis/trans isomerase and, as a foldase, it accelerates the rate-
limiting steps along the folding pathway, but it also acts as a
classical molecular chaperone (Fischer et al., 1989; Freskgard
et al., 1992). We originally identified it as a candidate protein
biomarker in PBMC of ALS patients with classical disease
onset, where it is upregulated also in association with disease
progression (Nardo et al., 2011). We next found that mutant
SOD1 and TDP-43 are substrates of PPIA (Lauranzano et al.,
2015). In fact, in absence of PPIA increased levels of mutant
SOD1 and TDP-43 were recovered in the aggregates isolated
from the spinal cord of SOD1G93A mice that had also an
anticipation of the onset and an acceleration of the disease
progression.
HSP90 is one of the most abundant and conserved cytosolic
heat shock proteins. It is responsible for the correct folding of a
number of newly synthesized proteins and for the refolding of
misfolded proteins associated with neurodegenerative diseases,
including TDP-43 (Basso et al., 2009; Daturpalli et al., 2013;
Carlomagno et al., 2014; Schirmer et al., 2016). Accordingly, we
found it entrapped in the aggregates isolated from the spinal
cord of SOD1G93A mice already at a presymptomatic stage of
the disease and from spinal cord tissues of sporadic ALS patients
(Basso et al., 2009).
GRP78 is a major ER chaperone and a key regulator of the
unfolded protein response. Disturbance of ER homeostasis is a
common feature of ALS and defects in ER chaperones caused
motor dysfunction in experimental models of ALS (Atkin et al.,
2008; Saxena et al., 2009; Woehlbier et al., 2016). Loss of one copy
of SIL1, a GRP78 cofactor, anticipated disease onset and reduced
life span in the SOD1G93A mouse model (Filézac de L’Etang et al.,
2015), however, the precise role of GRP78 in ALS remains to be
determined. In Alzheimer’s disease, studies in vitro indicated that
it may be part of the defense mechanisms of the cell by inhibiting
the generation of amyloid-β peptides (Yang et al., 1998; Hoshino
et al., 2007).
DJ-1 is a multifunctional stress response protein with a strong
and homogenous expression in all CNS regions (Bader et al.,
2005). DJ-1 mutations cause early onset autosomal recessive
Parkinson’s disease (Bonifati et al., 2003). It is a chaperone for
alpha synuclein and was shown to be protective against oxidative
stress by upregulating HSP70 (Shendelman et al., 2004; Zhou
et al., 2006; Batelli et al., 2008). In the SOD1G93A mouse model
increased oxidized/inactive DJ-1 forms were found in brain
tissues and knocking out DJ-1 has led to an accelerated disease
course and shortened survival time (Lev et al., 2009, 2015).
Interestingly, we found that PPIA, HSP90, GRP78, and DJ-1
are present at lower levels in PBMC from patients with an early
onset disease, and have a similar behavior in PBMC and spinal
cord of an early onset SOD1G93A mouse model, in which defects
in protein quality control have been previously observed (Marino
et al., 2015). These proteins, both in patient PBMC and mouse
samples, are less upregulated in early ALS than in late ALS, and
for PPIA this is evident already at a presymptomatic stage of the
disease in the soluble fraction of the mouse spinal cord (Marino
et al., 2015). The bases of these differences in early and late-
onset disease are solely genetic and yet unknown in the case of
the SOD1G93A mouse models, but exogenous factors cannot be
excluded in the patients. For example, it has been reported that
exposure to certain toxins lead to GRP78 downregulation (Yang
et al., 2000; Namba et al., 2010).
CONCLUSION
These data suggest that a failure in the response to stress and
a reduced ability to upregulate protective proteins may increase
susceptibility to ALS. This is in agreement with the fact that
vulnerable motor neurons have a high threshold for induction
of the protective heat shock response and a higher sensitivity to
ER stress (Batulan et al., 2003; Saxena et al., 2009). A protein
signature comprising a panel of proteins involved in proteostasis
may underline a subset of patients more susceptible to the disease
and may help to stratify patients for more targeted ALS clinical
trials. These observations further strengthen the notion that
proteostasis maintenance by the ubiquitin–proteasome system,
autophagy and ER, is a central issue in ALS, and therapeutic
approaches aiming at boosting the protein quality control system
might be a promising therapeutic strategy. Arimoclomol, a small
molecule that acts as a co-inducer of the heat shock response
by prolonging HSF1 activation and upregulating a number of
proteins such as HSP60, HSP70, HSP90, and GRP94, has shown
to be effective in several experimental models of motor neuron
degeneration including the SOD1G93A mouse (Kalmar et al.,
2014). A Phase II clinical trial in ALS patients has shown
that the drug is safe and well tolerated (Cudkowicz et al.,
2008) and is now under investigation in a PhaseII/III clinical
trial in SOD1 positive familial ALS patients (ClinicalTrials.gov
identifier: NCT00706147). Colchicine, a FDA-approved drug that
was identified by a high-throughput screening as enhancer of the
expression of HSPB8, a key player of the protein quality control
system, has demonstrated to facilitate the removal of TDP-43
aggregates by autophagy (Crippa et al., 2016).
Finally, this work confirmed that PBMC are valuable clinical
samples since they reflect traits of the disease observed in the
central nervous system and that total TDP-43 protein level in
PBMC can discriminate ALS patients from healthy controls,
as observed in a previous work using the same assay (Nardo
et al., 2011). We also further confirmed that the experimental
setting in which both 129Sv and C57 SOD1G93A mouse strains
are examined is useful to study disease susceptibility and
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test novel therapeutic approaches aimed at addressing disease
heterogeneity.
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